Table 1.
Prognostic factors that affect survival of patients
| Subgroup | N (%) | 3 year survival (%) | Median survival (months) | P |
|---|---|---|---|---|
| Age | ||||
| <65 | 100 (68) | 33 | 22 | 0.026 |
| ≥65 | 48 (32) | 21 | 16 | |
| Sex | ||||
| Men | 135 (91) | 29 | 19 | 0.468 |
| Women | 13 (19) | 24 | 21 | |
| Histopathology | ||||
| 1SCC | 100 (68) | 32 | 30 | 0.172 |
| Adenocarcinoma | 27 (18) | 27 | 18 | |
| 2NOS | 21 (14) | 19 | 17 | |
| Performance score | ||||
| 3ECOG0 | 53 (39) | 21 | 17 | 0.273 |
| ECOG1 | 57 (42) | - | 24 | |
| ECOG2 | 25 (19) | - | 13 | |
| Stage | ||||
| 3A | 7 (49) | 37 | 24 | 0.033 |
| 3B | 75 (51) | 21 | 14 | |
| Treatment | ||||
| Sequential 4CT+5RT | 26 (17) | 15 | 15 | 0.023 |
| Concurrent 6CRT | 122 (83) | 30 | 21 | |
| Treatment | ||||
| CRT | 35 (29) | 43 | 29 | 0.791 |
| 7Ind/Cons+KRT | 87 (71) | 27 | 20 | |
| RT dose | ||||
| <60 Gy | 15 (10) | 0 | 7 | <0.001 |
| ≥60 Gy | 133 (90) | 30 | 21 | |
| Weight lose | ||||
| No | 96 (71) | 20 | 10 | 0.573 |
| Yes | 39 (29) | 25 | 18 |
SCC, Squamous cell carcinoma; NOS, Not otherwise specified; ECOG, Eastern Cooperative Oncology Group; CT, Chemotherapy; RT, Radiotherapy; CRT, Chemoradiotherapy; Ind/Cons, Induction/Consalidation